Reporting from Chinese language media outlet Yaozh, based on recently issued annual financial reporting, shows the leading R&D spenders among the (predominantly mainland Chinese) biotech companies listed on the Hong Kong Stock Exchange (HKEX). Local heavyweight Beigene invested almost three times as much on R&D last year as its nearest competitors, a full 72.1 percent of its USD 24.86 revenues. Other big research investments came from CSPC and Sino Biopharmaceutical. See below for the full list.  

Made with Visme Infographic Maker